AlgiPharma wins research grant from CFF

AlgiPharma has received a research grant from CFF, the Cystic Fibrosis Foundation, to perform an in-vitro study of its proposed cystic fibrosis medicine. The grant is administered by the Cystic Fibrosis Foundation Therapeutics Inc., a subsidiary of the CFF. The research shall be performed in the United Kingdom.

About the Cystic Fibrosis Foundation: The Cystic Fibrosis Foundation is the leading organization devoted to curing and controlling cystic fibrosis. Headquartered in Bethesda, MD, USA, the Foundation funds CF research, has 80 chapter and branch offices throughout the United States, and supports and accredits a nationwide network of 115 CF care centers, which provide vital treatments and other CF resources to patients and families. For more information, visit www.cff.org.
To advance the search for a cure, CFF has invested nearly $230 million in promising scientific research in the pharmaceutical and biotechnology industries since 1998. As a result, the Foundation has nearly 30 potential therapies in its drug discovery and development pipeline. Any one of these could have a profound impact on the lives of people with cystic fibrosis.

For further information, please contact:
Yngvar P. Berg, CEO; yngvar.berg@algipharma.com

April 2011

AlgiPharma wins NFR funding for basic research projects on biofilms

The Research Council of Norway (Norges Forskningsråd (NFR)) has awarded AlgiPharma grants for two new projects “Biofilm” and “Epipharm II” representing a continuation and expansion of the NFR support for AlgiPharma’s alginate oligomer research efforts. These grants are administered under the NFR program for User directed Innovation Arena.

For further information, please contact:
Philip D. Rye R&D Director, +47 97503033; phil.rye@algipharma.com

June 2008